Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Neoplasms
Interventions: DRUG: GSK525762|DRUG: Placebo|DRUG: Fulvestrant
Sponsor: GlaxoSmithKline